Uloro is called lysergic insulin, and Novozymes is called menopausal insulin, both are rapid-acting human insulin analogs, and there is no essential difference between the two in terms of therapeutic efficacy. The main difference between the two human insulin analogs lies in the different chemical structures. Lysergic insulin is made by pairing two amino acids on human insulin, while Mentholatum insulin is by replacing one amino acid on human insulin. The two modified human insulin analogs have a faster onset of action and a shorter maintenance time compared to regular human insulin, and are more suitable for postprandial blood glucose control, which can be injected immediately before a meal, without having to be injected half an hour in advance like human insulin. Their glucose-lowering effect and glucose-lowering stability are better than that of human insulin, and the chance of various side effects is smaller than that of human insulin.